The program included several clinical trials (5 key trials) and encompassed roughly 3,500 patients. In conjunction with standard care, alirocumab demonstrated during the twenty fourth weeks on the trial that there was a reduction of LDL. This study was compared to two control groups: a group that received a placebo and one that received standard care. The American Pharmacists Association states that LDL was reduced by 36 to 58 percent across the five studies, illustrating the effectiveness of alirocumab working with statins. Nevertheless, there were common adverse reactions, such as nasopharyngitis, influenza, and injection site
The program included several clinical trials (5 key trials) and encompassed roughly 3,500 patients. In conjunction with standard care, alirocumab demonstrated during the twenty fourth weeks on the trial that there was a reduction of LDL. This study was compared to two control groups: a group that received a placebo and one that received standard care. The American Pharmacists Association states that LDL was reduced by 36 to 58 percent across the five studies, illustrating the effectiveness of alirocumab working with statins. Nevertheless, there were common adverse reactions, such as nasopharyngitis, influenza, and injection site